Defining and Treating Borderline Resectable Pancreatic Cancer.
Opinion Statement: Patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC) should receive preoperative chemotherapy with or without radiation therapy, with the intent to eradicate occult metastatic cancer cells, to select patients with a "locally dominant cancer phenotype" for...
| Publicado en: | Current Treatment Options in Oncology Vol. 21; no. 9 |
|---|---|
| Autores principales: | , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Sep2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=145695121&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 145695121 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Sep2020 vid: 21 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 145695121 145695121 NLM32725270 145695121 10.1007/s11864-020-00769-1 NLM32725270 145695121 ppct: 1 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Defining and Treating Borderline Resectable Pancreatic Cancer. aug: au: Perri, Giampaolo Prakash, Laura Katz, Matthew H. G. affil: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 17.6058, Unit 1484, 77030, Houston, TX, USA sug: subj: Pancreatic Neoplasms Therapy Pancreatic Neoplasms Diagnosis Pancreatic Neoplasms Etiology Pancreatic Neoplasms Mortality Human Treatment Outcomes Disease Susceptibility Preoperative Care Disease Management Prognosis Neoplasm Staging Methods Combined Modality Therapy ab: Opinion Statement: Patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC) should receive preoperative chemotherapy with or without radiation therapy, with the intent to eradicate occult metastatic cancer cells, to select patients with a "locally dominant cancer phenotype" for whom local therapies might be most effective, and to reduce the anatomic extent of tumors to facilitate surgical resection. The administration of preoperative therapy may also be a useful strategy to deliver the maximum load of chemotherapy to patients with BR PDAC, since as many as half of patients will never qualify for adjuvant treatments following pancreatectomy due to postoperative morbidity or disease progression. Patients with BR PDAC should be categorized at diagnosis on the basis of anatomical, biological, and conditional criteria and should be offered induction systemic chemotherapy with close monitoring for toxicity, followed by administration of (chemo)radiation in selected cases. Patients should be restaged after systemic therapy and, if used, (chemo)radiation. Patients who continue to show disease response or disease stability without signs of progression should be considered for pancreatectomy; better measures of response to therapy are needed. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|